Trial Profile
A retrospective study evaluating long term safety and efficacy of treatment with omalizumab in patients with severe persistent allergic asthma.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Jul 2017
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Allergic asthma
- Focus Adverse reactions; Therapeutic Use
- 12 Jul 2017 New trial record
- 24 May 2017 Results of 2 year follow up, presented at the 113th International Conference of the American Thoracic Society